Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

6.125 -0.615 (-9.12%)

Streaming Delayed Price Updated: 2:19 PM EDT, Jul 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

3 Growth Stocks That Could Go Parabolic in 2024 ↗

January 15, 2024

These innovation-oriented companies could take flight this year.

Via The Motley Fool

AI-Focused Drug Discovery Stocks Index Up 26% In December ↗

December 29, 2023

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.

Via Talk Markets

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

December 20, 2023

From AbCellera Biologics Inc.

Via Business Wire

AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week ↗

December 17, 2023

A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.

Via Talk Markets

Topics Artificial Intelligence

Earnings Preview: AbCellera Biologics ↗

August 02, 2023

Via Benzinga

AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗

December 16, 2023

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

Via InvestorPlace

Topics Artificial Intelligence

The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week ↗

December 11, 2023

If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to...

Via Talk Markets

Topics Artificial Intelligence

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November ↗

December 06, 2023

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

Via Talk Markets

Topics Artificial Intelligence

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

November 16, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

November 03, 2023

From AbCellera Biologics Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 03, 2023

Via Benzinga

AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript ↗

November 03, 2023

ABCL earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 02, 2023

Via Benzinga

AbCellera Reports Q3 2023 Business Results

November 02, 2023

From AbCellera Biologics Inc.

Via Business Wire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

November 01, 2023

From AbCellera Biologics Inc.

Via Business Wire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

November 01, 2023

Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader

From Prelude Therapeutics, Inc.; AbCellera

Via GlobeNewswire

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

October 31, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

October 11, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Two T-Cell Engager Presentations at SITC 2023

September 27, 2023

From AbCellera Biologics Inc.

Via Business Wire

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

September 20, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

September 13, 2023

From AbCellera Biologics Inc.

Via Business Wire

Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects ↗

August 31, 2023

Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL),

Via Benzinga

3 AI Stocks You’ll Regret Not Buying Soon ↗

August 08, 2023

AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in.

Via InvestorPlace

Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

August 04, 2023

Gainers Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition.

Via Benzinga

Apple, Fortinet, Microchip Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

August 04, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript ↗

August 04, 2023

ABCL earnings call for the period ending June 30, 2023.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 03, 2023

Via Benzinga

AbCellera Reports Q2 2023 Business Results

August 03, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing

July 24, 2023

From AbCellera Biologics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.